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Abstract
Numerous studies have indicated that radiation therapy reduces the risk of the local
recurrence of breast cancer in several cases and that it has increased the overall survival rate.
Although radiation therapy is beneficial for the treatment of breast cancer, it is known to increase
the risk of both radiation toxicity and secondary breast cancer. In left-sided breast cancer,
radiation therapy treatment often leads to the heart and its components—such as the left ventricle
and left anterior descending artery—being exposed to high doses of radiation because of the
proximity of the heart to the left breast, resulting in cardiac complications several years after the
treatment. Further, it is important to deliver low doses to the left lung to reduce the risk of
pneumatic and lung fibrosis, particularly for patients with long survival rates. Modern 3D
techniques can deliver a reduced dose to the cardiac components and lungs. However, the risk
of radiation to cardiac components remains unclear, because complications are directly related
to radiation dose. Treatment techniques play an important role in sparing organs at risk (OAR)
without compromising the target. Specific techniques for left-sided breast cancer treatment result
in higher cardiac and pulmonary toxicity, which has been shown to be related to increased risk of
heart and lung diseases.
In the first two studies in this dissertation, the dose-volume metrics of the OAR were
calculated for different techniques for treating patients with left-sided breast cancer. In the first
study, the supine free-breathing (SFB), deep inspiration breath-hold in supine (SDIBH), and prone
free-breathing (PFB) techniques were evaluated to reduce the cardiac and left lung doses. Most
left-sided breast cancer patients undergoing radiation treatment are treated using the SFB
technique. The deep inspiration breath hold (DIBH) technique has been proven to reduce the
v

cardiopulmonary doses for breast radiation therapy. In DIBH, a patient takes a deep breath and
holds the breath during irradiation. The prone position is another technique used to reduce doses
to OAR. Our first study is the only one that compares the dose-volume metrics of OAR for the
same patient scanned in three different positions with respect to breast size. This study
demonstrates a novel, yet simple and cost-effective, technique to implement the DIBH technique
by utilizing lasers and high definition cameras. This method can be used in clinics without the
need to purchase expensive breath-hold equipment to implement the DIBH technique clinically.
In our second study, we included the prone deep inspiration breath-hold (PDIBH) method in
addition to SFB, SDIBH, and PFB techniques to evaluate the OAR. In this study, the normal tissue
complication probability (NTCP) is calculated to determine the probability of damage induced on
normal tissues for given radiation doses to OAR. This study is the first to perform a biological
evaluation based on radiobiological models for each OAR with specific endpoints in left-sided
breast cancer treatment. The NTCP values for each OAR are compared and evaluated in addition
to dose-volume histogram-based evaluations for four different techniques. In the third study, the
surface dose of the prone and supine treatments was evaluated. Skin dose can be an important
factor regarding the outcome and cosmesis for patients. Further, a superficial dose has a large
variance that depends on the incident angle relative to the surface. Understanding surface dose
dosimetry in the tangential or oblique beam is important to evaluate the skin dose, because a
higher dose leads to toxicity and a lower dose can lead to recurrences. This study also evaluates
superficial doses in the prone and supine positions with respect to two different grid sizes.
This dissertation establishes a basis for a comprehensive evaluation to help clinicians
decide on the best possible treatment techniques for left-sided breast cancer patients. Patients
with healthy lungs can be recommended the DIBH technique for a reduced dose to cardiac
components, whereas patients with compromised lung function can be recommended the prone
technique to spare the OAR. The clinician must be careful of lower skin dose when treating
patients using the prone technique, particularly for tumor bed close to the skin surface.
vi

Chapter 1: Background
1.1 What is Cancer?
Cancer is caused when the growth of cells becomes uncontrollable, consequently forming
a mass or tumor. Normal and healthy cells divide systematically, stopping reproduction and
growth when they touch other cells. On the contrary, cancer cells continue to divide disorderly
and constantly grow. Cancer cells, which make up tumors, grow and reproduce rapidly.
1.2 What is Breast Cancer?
Cancer that develops in breast is known as breast cancer. Thus, breast cancer is a
malignant tumor arising from the cells in the breast. Breast cancer can originate in different parts
of the breast. A breast comprises three main parts, namely, glands, ducts, and connective tissue.
The glands produce milk, and ducts are passages that carry milk to the nipple. The connective
tissue connects and holds all the parts together. The most common breast cancers are ductal
carcinoma, invasive ductal carcinoma, lobular carcinoma, and invasive lobular carcinoma. Breast
cancer occurs predominantly in women but could affect men as well.
1.3 Treatment for Breast Cancer
Primary methods to treat breast cancer consist of surgery, adjuvant radiation therapy (RT),
and systematic medical therapy, e.g., chemotherapy and endocrine treatment.1 The most
commonly used breast treatment methods are briefly explained below; because the primary
research topic is RT, it is explained in more detail.

1

1.3.1 Surgery
According to the American cancer society, most breast cancer patients undergo some
form of surgery as part of their treatment.1 Two main types of surgery are available to remove
breast cancer.

Figure 1.1 Anatomy of normal breast tissue.
1.3.1.1 Breast-Conserving Surgery (Lumpectomy)
This surgery involves the removal of only part of the breast containing the cancer. In this
surgery, only tumor and some surrounding breast tissue around the tumor is removed. This
method conserves the breast and is thus called breast-conserving surgery (BCS).
1.3.1.2 Mastectomy
This surgery involves the surgical removal of the entire breast and some surrounding
tissue. A few women undergo double mastectomy or bilateral mastectomy in which both breasts
are removed.
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1.3.2 Systematic Medical Therapy
Systemic therapy refers to the treatment of the circulation of pharmaceuticals in the
bloodstream after injection or ingestion. This treatment affects all parts of the body because blood
circulates across the whole body. Although chemotherapy, hormone therapy, and targeted
therapy are systemic medical treatments, each has a distinct underlying mechanism. They can
be further categorized into neoadjuvant therapy and adjuvant therapy.
1.3.2.1 Neoadjuvant Therapy
Administering systematic therapies on patients before surgery is known as neoadjuvant
therapy, whose objective is to shrink the tumor, thereby making the surgical procedure less
extensive. Moreover, neoadjuvant therapy has been found to be as effective as adjuvant
therapy—which is performed after surgery—in terms of survival, disease progression, and distant
recurrence.1
1.3.2.2 Adjuvant Therapy
Administering systematic therapies after the surgery is known as adjuvant therapy.
Systemic therapy is given after surgery to kill undetected tumor cells remaining after the surgery.
Cancer that has spread from the breast to the other parts of the body is called metastatic breast
cancer. Metastatic breast cancer patients are considered good candidates for adjuvant therapy
because of the spread of the disease.1
1.3.3 Radiation Therapy
RT is one of the most widely used therapies to treat cancer. It uses ionizing radiation to
destroy malignant tumors, thus minimizing damage to normal tissues. RT damages the DNA
within the cancer cells, thereby destroying the ability of the cells to reproduce. The damaged
cancer cells are eliminated naturally by the body. Although normal cells surrounding the tumor
are affected by the radiation, they can repair themselves. The objective of RT is to destroy
cancerous cells by irradiating the target with radiation beams and simultaneously preserving the
surrounding healthy tissue.
3

About half of all cancer patients undergo radiotherapy as an independent treatment or in
combination with other treatment modalities, i.e., surgery and chemotherapy.1 The concept of
treating cancer with ionizing radiation was first used at the end of the 19th century. Since then,
technology has undergone major advancements and the current technology can offer increasingly
sophisticated treatment methods. To avoid undesirable side effects or radiation-induced cancer,
sparing as much normal tissue as possible is important when targeting the PTV. Accordingly,
various treatment techniques are being continuously developed to realize the objective of
maximizing the dose and radiation damage to the target volume and sparing the healthy tissues
surrounding it.
The treatment process using radiation involves three major processes, namely, computed
tomography (CT) scan, treatment planning, and RT treatment.
1.3.3.1 Computed Tomography Scan

Figure 1.2 Computed tomography scanner.
CT scan is an imaging procedure that uses special x-ray equipment to create images or
scan of areas inside the body. A typical CT machine used in RT is shown in Figure 1.2. The Xrays from the CT scanner pass through the body and are detected by detectors after exiting the
4

body. The CT scan images are used for contouring various normal surrounding tissues, organs
at risk (OAR), and target volumes. A CT scan of the treatment region is performed to obtain
accurate information on locating the tumor, OAR, and treatment planning. These 3D images are
sent to the treatment planning system for performing treatment planning.
1.3.3.2 Treatment Planning System

Figure 1.3 Eclipse Treatment planning system unit used for treatment planning.
Treatment planning systems (TPS) are of prime importance in the RT treatment
procedure. It is a sophisticated software where all the data of linear accelerators and their
characteristics are used to simulate the linear accelerator. The TPS is key to improved dose
calculation, distribution, and patient outcomes. The CT scan images are imported into the TPS
as the input data in the treatment planning process. Once the image datasets are loaded and the
tumors are identified, the CT scan images are used to contour the normal surrounding tissues or
OAR. CT images contain quantitative data that are expressed in Hounsfield units (HUs). Electron
densities are directly related to the linear attenuation coefficients of tissues in the photon beam
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path length.2 Thus, it is important to provide the correct relationship between HUs and electron
density in the TPS for accurate dose calculation by the algorithm.
The TPS then develops a complex plan for each beamlet to deliver radiation. The software
computes the expected dose distribution in the patient’s tissue, including variables such as tissue
type, energy, and tumor depth. Treatment beam shapes and dose distribution are chosen with
the intent to minimize the dose to critical structures and maximize the dose to the target based on
published guidelines.3
1.3.3.3 Linear Accelerator
The medical linear accelerator (LINAC) is the most used device for external beam RT
treatments for cancer patients. It delivers high-energy photons or electrons to the tumor volume
of the patient undergoing RT. These treatments are designed to damage the cancer cells while
sparing the healthy tissue around them. An electron gun produces electrons that are injected into
the waveguide. The LINAC employs microwave technology to accelerate electrons in a part of
the accelerator called the waveguide; subsequently, these electrons are collided with a heavy
metal target to produce high-energy x-rays, as shown in Figure 1.4a (schematic) and 1.4b (actual
image).
The patient lies on a moveable treatment couch that can be moved in multiple directions;
i.e., right, left, in, out, up, down; some couches can perform pitch and roll as well. The beam exits
the accelerator from the gantry. The gantry of the accelerator can be rotated a full 360 degrees
around the patient. The beam is usually shaped by a multi-leaf collimator (MLC) that is
incorporated into the head of the gantry. A modern-day LINAC usually consists of 120 MLCs, with
the MLC width varying from 0.25 cm to 1 cm. These high-energy photons are customized using
MLCs to conform to the shape of the patient's tumor. Specifically, the MLCs aid the irradiation of
the patient by shaping the tumor, with many different gantry angles being used by rotating the
gantry and the couch to maximize the dose to the target while sparing the surrounding OAR. The
major difference between 3D conformal therapy and intensity-modulated radiation therapy (IMRT)
6

(a)

(b)

Figure 1.4 a) Schematic and b) Actual image of medical linear accelerator.
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or volumetric arc therapy (VMAT) is that in 3D conformal therapy, the MLC and collimator helps
to form the shape of the target, whereas in IMRT and VMAT the software moves the MLCs to
modulate the beam to conform to the shape of the target.
1.4 Radiation Therapy Treatment Techniques
As patients now have a prolonged life expectancy, they could be at higher risk of
developing long-term complications because of radiation of OARs. Thus, different techniques are
being used to study the possibility of reducing dose to OARs without compromising the coverage
of target volume. As mentioned earlier, the current most common treatment techniques for breast
cancer include (but not limited to) the use of supine 3D Tangent technique, IMRT, and VMAT.
The 3D technique uses the MLC and the collimators to shape the beam to conform to the target
and spare the OAR in three dimensions. It helps maximize the dose to the target and spare the
healthy tissues. In addition, beam modifying devices such as wedges are included to shape the
dose around the target volume. The supine free-breathing (SFB) 3D tangent technique is
predominantly used over the others and has become a standard practice because of its easy,
reproducible, and practical set up. Thus, free-breathing in supine position is the most used
treatment technique for breast radiation treatment. A typical supine set up with the heart and left
lung, and left breast in a CT slice is shown in Figure 1.5(a). The arrows in Figure 1.5(a) represent
the volume of heart and left lung inside the treatment field edges, which is radiated. Although
technology has advanced in the last decade, the dose delivered in this position to the heart and
the left lung remains significant.
IMRT is a sophisticated method of three-dimensional (3D) conformal radiation therapy
(CRT). IMRT uses the MLC to modulate the fluences and thus optimizes the delivery of irradiation
to irregularly shaped tumor volumes. The IMRT technique thus has the capability to deliver
radiation treatment to concave volumes. This helps administer the maximum dose to target
volumes while sparing critical organs more than 3D CRT. VMAT is the latest technique to produce
IMRT-like dose distributions. IMRT uses static gantry angles while the MLCs move continuously
8

to modulate the intensity of the beam. By contrast, in VMAT, the gantry also rotates at varying
speeds and dose rates to deliver doses in single or multiple rotations of the gantry. Planning
studies comparing both techniques indicate that a better conformity and dose homogeneity,
shorter treatment time, fewer monitor units for treatment delivery, and better normal tissue sparing
are achieved with VMAT.
Many other 3D treatment techniques have been evaluated to reduce the dose to cardiac
components, such as the supine deep inspiration breath-hold (SDIBH) technique,4,5 prone freebreathing (PFB) technique,6-10 and the prone deep inspiration breast hold (PDIBH) technique11,12;
however, a consensus has not been reached over the superiority of a particular treatment
technique.4,13-18 Few studies have compared the SFB, SDIBH, and PFB techniques to evaluate
doses to OAR.10,19 In addition, newer techniques such as IMRT and VMAT have been used to
reduce dose to the OAR. Although modern techniques such as IMRT decrease the volume of the
heart and lung that receives high doses, a larger volume may receive lower doses owing to the
low dose spread associated with these techniques.20,21
Irradiation in the prone position (Figure 5(b)) is another method to minimize the doses to
heart and lungs.6,8,10,12,13,19,22,23 Studies have shown a reduction of irradiated lung volume in all
patients, and a few studies have shown a higher reduction of dose to the heart volume in the
prone position compared with the supine position.8,10,13,22 Further, the deep inspiration breath-hold
(DIBH) technique is used in combination with any of the above techniques to reduce the dose to
the heart.10,11,22,24-27 In DIBH, the patient takes a deep breath and holds the breath during radiation.
The DIBH has been proven to reduce cardiopulmonary doses in breast RT.5,10,19,22,28
In our study, we compare only the 3D techniques because they are predominantly used
for breast cancer treatment; we did not compare the treatments based on IMRT or VMAT
technique. Furthermore, 3D CRT, in conjunction with DIBH and prone techniques, is an alternative
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to free breathing-based 3D CRT. In this section, two techniques are demonstrated in addition to
the supine technique, i.e., the prone and DIBH techniques used in this dissertation are explained
briefly.
1.4.1 Prone Technique
In the prone technique, the patient is simulated and treated, lying on the abdomen to pull
the breast away from the heart.10,18,22 This changed shape, motion, and position of the breast and
OAR present in the treatment field raises unique concerns specific to prone breast irradiation. The
hanging down of the breast from the aperture of the positioning device results in a different dose
distribution relative to that in the supine position. The prone technique has become feasible and
reproducible with the beginning of CT scan-based treatment planning. This prone technique has
been developed to improve the dose distribution and homogeneity within the breast. It also helps
to reduce the volume of normal tissues irradiated during whole breast treatment. The dosimetry
of breast irradiation is improved by optimizing the shape of the breast, resulting in a reduction in
the magnitude of high-dose regions and isodose gradients in the breast PTV. Reduction in the
scale of high dose regions in the breast tissues can be achieved by optimization of the MLCs to
conform to the shape of the breast. Improved dose homogeneity and reduction of overdosage
within the PTV in the prone technique have been associated with better cosmetic outcomes.
Prone breast irradiation has generally been recommended for women with large
pendulous breasts to decrease acute and late toxicities. In addition, this technique has been
proven to be advantageous for most patients because it consistently reduces—if not eliminates—
the inclusion of the heart and lungs within the field. The latest technological developments in linear
accelerators and the increased accuracy of treatment planning algorithms, coupled with better
imaging and verification reproducibility, have made an accelerated fraction scheme in which 42.66
Gy are delivered in 16 fractions is possible.6,29,30

10

(a)

(b)

Figure 1.5 Prone and supine CT images showing the heart, lungs, and left breast contours. Yellow
arrows represent the volume of organs in the radiation treatment field in a) Supine technique and
b) Prone technique. Please note that the prone technique has lower heart and lung volumes in
the treatment field compared with those of the supine technique.
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1.4.2 Deep Inspiration Breath Hold (DIBH) Technique
The DIBH technique can be used to decrease heart, LV, and LAD doses during left-sided
breast cancer radiation treatment. During both CT simulation and RT treatment, the patient takes
a deep breath and holds it for a period, during which radiation can be administered. The technique
is based upon the theory that during inspiration the expansion of the lungs and the flattening of
the diaphragm pull the heart away from the chest wall. Thus, during inspiration, the heart and the
target volume are separated, and a reduction in lung density is seen. This allows for a decrease
in the volume of heart in the radiation beam, which reduces dose to the heart, as shown in Figure
1.6.31 In addition, a fused CT image of SFB with the SDIBH technique for the same patient, along
with the heart position in both scans and radiation field edge, is shown in Figure 1.6. Please note
how heart volume is pushed away from the chest wall in the SDIBH technique, thus sparing heart
(Figure 1.6). The DIBH can be alternatively used for prone breast irradiation; the two techniques
can be (and have been) used in conjunction with the PDIBH technique as well.22 The fused CT
image of PFB with the PDIBH technique for the same patient, along with the heart position in both
scans and radiation field edge, is shown in Figure 1.7; similar observation is made for PFB and
PDIBH scans, which indicate that the heart is pushed away from the chest wall.
Both the initial imaging and the treatment delivery are performed during inhale breathhold, which may be voluntary or involuntary. The DIBH methods, which are based on voluntary
breath-hold and rely on external surrogates for monitoring, could have the disadvantage of
variability in patient immobilization, which may not be quantified well during the imaging
procedure.32-34 Involuntary breath-hold, on the other hand, uses an active breathing control (ABC)
device, which holds the patient’s lung at a specified and reproducible volume.35,36 A drawback of
all the DIBH methods is that the patients cannot always tolerate breath-hold.
In this study, we propose an in-house technique to verify voluntary breath-hold without
using expensive technology for monitoring breath-hold using RPM system or involuntary breathhold based device to consistently achieve breath-hold. In our clinic, we used room lasers, which
12

are used for patient set up, along with high-definition cameras to implement the DIBH technique
for the treatment.

Figure 1.6 Fused SFB and SDIBH CT scan images of the same patient. Please note the position
of the heart in SFB and SDIBH scans with respect to the radiation field edge.

Figure 1.7 Fused CT scan images of the PFB and PDIBH techniques of the same patient. Please
note the position of the heart in PFB and PDIBH scans with respect to the radiation field edge.
13

1.5 Design of Dissertation
We used the European format of introduction, discussion, and conclusion based on the
three studies attached in the appendix section for this dissertation. Owing to the similarity of the
topics between studies, they could overlap.
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Chapter 2: Introduction 1
Breast cancer (BC) is a major global health problem among women, with about 1.7 million
new cases diagnosed annually.37 Breast cancer mortality rate is the second highest after lung
cancer for women in the United States.38 Approximately 1 in 8 women is diagnosed with invasive
breast cancer in their lifetime and 1 in 39 women die of breast cancer.39 Adjuvant radiotherapy
has been used for the treatment of breast cancer since the 1930s. The first randomized trials for
adjuvant RT were reported by the end of 1940s. Several randomized trials conducted since then
have indicated clinically significant reduction of local recurrence and no adverse effect on the
overall survival. Combined modality, breast conserving surgery, and chemotherapy, followed by
whole breast RT, is currently becoming a standard in the treatment of early-stage breast cancer.40
Many women with early stage breast cancer undergo radiation treatment as part of their
cancer management.10 More than 20 years of follow-up data confirm that, after breast
conservative surgery, higher risk of local recurrence is present. However, women undergoing
breast conservative surgery followed by radiation treatment have the same long-term survival
similar to that in mastectomy.41 It has been shown that RT reduces the risk of breast cancer local
recurrence in a large number of cases, which has led to an increased overall survival rate.42 A
large meta-analysis by early breast cancer trials found that patients treated without RT after
breast-conserving surgery have 26% chance of local recurrence at five years follow up, compared
with 7% in patients, who were administered RT.42 The analysis further indicated that, at 15 years

1
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after diagnosis, an absolute risk reduction of 5.4% exists in breast cancer mortality with RT after
breast-conserving therapy, compared with no RT after breast conserving therapy42.
Although RT to breast is beneficial, it is known to increase both the radiation toxicity and
secondary breast cancer.43 Specific techniques and treatment for left-sided breast cancer lead to
higher cardiac and pulmonary toxicity, which have been shown to be related to increased risk of
heart and lung diseases.40,42-45 It has been considered that the primary reason for higher
complication and mortality in left-sided breast cancer is the proximity of the heart to the radiation
beams, which can result in the delivery of high doses to the heart. This can lead to higher risk of
cardiac complications to the patient undergoing RT. During regular breathing, the heart moves in
and out of the radiation beams, often in an irregular and unpredictable pattern. It is difficult to
predict the correct dose to the heart owing to uncertainties in breathing motion and its correlation
to the position of the heart in the treatment field. Thus, it can be challenging to predict the accurate
dose-volume received by the cardiac component in the free breathing technique.
Darby et al.46 have shown that an increase of 1 Gy in mean dose to the heart results in a
7.4% relative increase of major coronary events; however Taylor et al.45 have indicated a lower
risk based on a recent dosimetry study. This study further demonstrated that exposure of heart to
the ionizing radiation during RT for breast cancer significantly increases the rate of ischemic heart
disease. Another research compared a group of irradiated patients and non-irradiated patients,
and showed a significantly higher non-breast cancer-related mortality, primarily for heart disease
(R.R, 1.27) and lung cancer (R.R, 1.78).42 A retrospective study compared the ratio of patients
receiving radiation to left-sided and right-sided breast cancers and died of heart disease. The
cardiac mortality ratio was 1.21, 1.08, and 0.99 for patients diagnosed between 1973–1982,
1983–1992, and 1993–2001, respectively.43 Thus, the advantage of RT on survival rate was
overshadowed by an increased risk of non-breast cancer-related deaths. Several investigations
showed that the leading cause for these deaths was heart disease.43,46-48 However, these results
are based on data using older treatment modalities and radiation techniques. RT techniques and
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equipment have significantly improved since these reports were published. With the advent of
modern technology, radiation exposure to the heart and lung is currently lower than that in the
past. In spite of this improvement, a few studies have shown that patients receiving RT treatment
for left-sided breast cancer are at a higher risk of long-term cardiac morbidity after the treatment.4952

These results were further corelated to the heart volume exposed to radiation during

treatment.53,54
A few studies suggest that arteries are particularly sensitive to radiation, and the left
anterior descending artery (LAD) is one of the typical sites of origin of ischemic heart disease.51,52
It is further recommended that minimizing the absorbed dose to heart and LAD must be a priority,
until evidence is found for a threshold absorbed dose below which no additional risk of cardiac
morbidity and cardiac mortality is present.55 In addition to cardiac complication, an increase in
lung complications with increased absorbed lung dose is present.43,56 The lung cancer mortality
for ipsilateral lung cancer was higher than that for contralateral lung cancer for the women who
developed lung cancer after undergoing breast RT.43 The increased absorbed lung dose further
increases the incidences of radiation pneumonitis.56
In left-sided breast cancer patients, parts of the heart, left ventricle (LV), LAD, and the left
lung are usually inside the treatment field, and are considered as OAR. Various techniques such
as DIBH and prone position have been used since then to spare the OAR without compromising
the breast planning target volume (PTV) coverage. A few studies have compared the SFB and
SDIBH or SFB and PFB techniques; however, no study has compared the dose for heart, LV,
LAD, and left lung with respect to breast PTV in three different positions on the same patient. In
our study, instead of commercially available gating systems, we developed an inhouse technique
to use a high-definition camera to check the position of the patient during treatment with respect
to lasers, as explained in section 2A. It is a simple, quick, and cost-effective technique that passes
on the benefits of the DIBH techniques to the patients and eliminated the need for expensive
devices to implement DIBH in clinics.
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Recently, radiobiological evaluation tools have become available in many treatment
planning systems. Normal tissue complication probability (NTCP) tool could be used to
biologically evaluate the plan along with dose-volume histogram (DVH)-based evaluation for
OAR.5,56,57 Biological parameters, when applied to these biological models, help predict the
biological effects on OAR, and are believed to be more directly correlated with treatment outcome
than the DVH based parameters.58,59 Our second study additionally involved biological evaluation
of the OAR in four treatment positions in addition to commonly used dosimetric evaluation. Our
study is the first to perform a biologic evaluation on OAR of left-sided breast cancer patients and
calculate the NTCP for each treatment position of every patient. The radiobiological model and
radiobiologic evaluation are further explained in section 2.3.
Skin dose in breast cancer radiation treatment is another important factor regarding not
only the outcomes but also the cosmesis. The skin toxicity is often considered a dose-limiting
factor.60,61 Radiation dermatitis has consistently been a concern for high dose treatments for
radiation oncologists.62,63 Skin dose toxicity influences the tolerance of treatment by patients and
the cosmetic outcomes of breast cancer patients.64-68 However, a recent study by Katz et al.69
provided a case report of inadequate skin dose that leads to skin recurrence in the prone
treatment technique. Therefore, evaluating the dose delivered to the skin to avoid recurrences,
and (particularly) underdosing tumors near the surface in breast RT, are of significant interest.
Generally, the surface/skin dose depends on the incident beam angle, field size, source
to skin distance, beam energy, and beam modifying devices. Typical prone and supine set ups
with gantry angle relative to the skin surface are shown in Figure 2.1. In our third study, we
hypothesized that a beam incidence angle close to perpendicular in the one breast technique
could result in lower superficial dose compared with the supine position, where the breast is
treated at a tangential angle of 45–55⁰. Such a steep angle produces an increased surface dose
based on the obliquity factor defined by Gerbi et al.70 Das et.al71 showed that a smaller grid size
can produce a more accurate dose calculation in the buildup region. The smallest grid size
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available in the Eclipse version 13.7 is 1 mm; thus, we chose a grid size of 1 mm and clinically
used 2.5 mm to evaluate the dose in the superficial region. Thus, understanding the skin dose for
each treatment technique helps radiation oncologists in choosing the appropriate treatment plan
to elicit positive outcomes.
In this study, organ contouring, treatment planning, and dosimetric evaluation were
performed on more than 100 patients, and more than 300 treatment plans were created and
evaluated. Biological evaluation was performed on 100 treatment plans. For consistency,
contouring on all CT scans was performed by a radiation oncologist in accordance with the
national guidelines, and all the treatment plans were created by a physicist. Treatment planning,
dosimetry, laser-based DIBH, and biological evaluation procedures are explained briefly in the
next section.
2.1 Treatment Planning and Dosimetry
After the CT scans were obtained, the images were transferred to the treatment planning
system. At our institute, for the first study, we used the Eclipse planning system V11 (Varian
Medical System version 11). Furthermore, the Anisotropic Analytical Algorithm (AAA Version
11.0.31) was used for calculations, and the grid size was set to 2.5 mm for the first and second
studies. For the second and third studies the calculations were performed in the Eclipse (Varian
Medical Systems Inc., Version 13.7) TPS using the Anisotropic Analytical Algorithm (AAA; Version
13.7) for both 1 mm and 2.5 mm calculation grid sizes. Our breast radiation oncologist contoured
the breast PTV, heart, LV, LAD, and contralateral breast of each patient based on the RTOG130424

guidelines

and

RTOG

Breast

Cancer

Atlas

for

planning

(https://www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.aspx). According to the
atlas, the breast was defined as an all apparent CT glandular breast tissue, considering the RTOG
consensus definition of anatomical borders. The cranial border was defined as the second rib
insertion, the caudal border was defined as the loss of CT apparent breast tissue, and the anterior
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(a)

(b)

Figure 2.1 Typical beam placement for (a) Prone and (b) Supine set up for left breast. Please
note the gantry angle with respect to the skin surface.
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boundary was defined as the skin. The posterior boundary was the anterior aspect of the
pectoralis muscles. The medial border was the sternal-rib junction and the lateral border was at
the mid-axillary line.
The LAD was defined as the vessel that descends anteriolaterally from the anterior
interventricular groove to the apex of the heart.72 Cardiac contouring started superior at the level
of great vessel insertion into the heart and extended inferior to the apex of the heart. The contours
were drawn by a single physician. The lungs were contoured using an automatic segmentation
tool available in Eclipse TPS, and the lung contours were manually edited by the physician as
needed. The breast PTVs were cropped by 5 mm from the skin surface for planning because the
dosimetry in the buildup region is not well defined. 71 The contralateral breast was not cropped
from the skin surface.
For treatment planning, heterogeneity correction was turned on for all the calculations.
Opposing tangential beams with Field in field techniques (FIF) were used for planning. All the
treatment plans were calculated only using a 6 MV beam, and wedges were not used in any plan.
Treatments for all patients were planned using the hypo-fractionated fractionation scheme defined
by Whelan et al.73 The doses were prescribed as a total dose of 42.56 Gy in 16 fractions. The
plan was normalized to the isocenter placed in the PTV. As per the RTOG protocol, a margin of
7 mm was given to PTV to form the field shapes using MLC.74 The most optimal plan was made
for each patient on each scan to compare the plans. The guideline was to have a minimum of
95% of PTV receiving 100% of the prescribed dose, with no more than 5% of the PTV volume
receiving more than 110% of the dose, and simultaneously achieve maximum sparing of the OAR.
Further, DVHs were used to analyze the PTV, dose homogeneity, and doses to OAR. For OAR,
the dose parameters were used based on the evaluated organ. For heart and left ventricle mean
dose, V2.5, V5, V10, V20, and V30 were recorded; for LAD mean dose, V2.5, V5, V10, and V20
were recorded; for lung mean dose, V10, V20, and V30 were recorded.
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2.2 Laser-Based DIBH
For DIBH, our institution developed a technique using lasers to mark the position of
patients in the FB and DIBH positions. Before scanning the patient, the breast tissue was marked
with radio-opaque wire by a radiation oncologist. The patients were first scanned in the FB
position. Patients were first marked in the medial and lateral direction with respect to lasers in the
CT room while breathing freely; they were then coached to take a deep breath and hold it i.e.,
DIBH. New positions on the patient's skin in the medial and lateral positions were marked again.
Now the patient has two marks, one representing the FB position and the second the DIBH
position with respect to lasers. The patients were asked to repeat DIBH, and a CT sim therapist
verified that they are consistently able to achieve the same position marked on their skin with
respect to lasers. Only the patients who followed the instructions, and those who held the breath
for 20 s were considered. Further, audio coaching was utilized to guide the patients for the second
scan to realize DIBH and release the breath-hold after scanning. High-definition cameras were
installed in the treatment room to clearly see the DIBH marks from outside the room. The highdefinition cameras were used to check the position of the patients during treatment with respect
to lasers to ensure the patient remains in the DIBH position. Table 2.1 represents the DIBH
simulation sheet created during CT simulation to record the shifts with respect to FB laser marks.
Please see the step by step procedure in the appendix A.

Table 2.1 Table for recording DIBH measurements.
Max breath-hold achieved (s)
Anterior FB marks and DIBH marks distance (mm)
Lateral FB marks and DIBH marks distance (mm)
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2.3 Radiobiological Modelling Biological Evaluation
Clinical radiobiology denotes the relationship between a delivered radiation dose and the
resulting biological effect on the tumor, normal tissues, and OAR. The goal of RT is to attain a
high local tumor control probability (TCP) at a low risk of normal tissue complication probability
(NTCP). NTCP models that are currently used in the TPS provide a simpler interpretation of
clinical radiobiology. Radiobiological evaluation is a complement to evaluation treatment plans
using dose distribution and the DVHs.56,57 The estimated probabilities of the clinical outcome are
evaluated in terms of NTCP for the OAR. These biological indices are used to compare rival dose
distributions, as well as fractionation schedules.
The main objective of RT is to deliver a sufficiently high dose to the tumor, so that all the
tumor cells are killed, along with minimal radiation-induced damage to the surrounding normal
tissue. In physical dose-based evaluations, the dose distribution and the dosimetric endpoints are
based on a clinician's individual clinical experience and published literature to define the dosevolume (DV) constraints. The physical quantities, such as DV, are conventionally used for plan
comparison and plan evaluation to find the coverage of target and radiation-induced complications
on the patient; it is generally evaluated using DVHs. In biological planning, the biological
endpoints are directly inputted and evaluate the actual effect of physical dose distribution on the
tissues using biological modeling. Furthermore, it is known that biologically related parameters
such as NTCP have a more direct correlation with radiation-induced complications than the DV
based parameters.58,59 Thus, they help avoid variability and a dependence on the clinician's
knowledge of dose-tissue response on radiation-related OAR complications.
This study calculates the NTCP of radiotherapy plans for 3D conformal RT of left-sided
breast cancer patients undergoing treatment. Biological modeling basically utilizes the DVH of a
given plan, biological parameters of the tumor type, and normal critical tissues to calculate the
normal tissue complication probability. In this study, two NTCP models—namely, NTCP-Poisson
LQ and NTCP-LKB, which are available in Eclipse TPS—were used with the default parameters
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listed in Table 3. The user can select a specific endpoint for the NTCP calculations.75-77 The
treatment plans were exported to the Eclipse biological evaluation module and the NTCP was
calculated from DVH. The NTCP Poisson LQ function was used to calculate the NTCP of heart,
LV, and LAD with cardiac mortality as the endpoint.57 Further, the NTCP-LKB model of the lung
with all the available endpoints in Eclipse TPS was used to calculate the lung NTCP.78-80 The
NTCP input factor and the associated endpoints for each OAR for the NTCP calculations are
listed in Table 2. Detailed mathematical equations of both the models are presented in appendix
E of this dissertation. The NTCP-LKB is based on the probit function,76 whereas the NTCPPoisson LQ model is based on cell survival models, Poisson statistics, and the relative seriality
model75.
A cell survival curve describes the relationship between the absorbed dose and the
fraction of cells that survive. The shape of the dose response curve indicates the tissue-specific
α/β-ratio. Normal tissue cells have α/β-ratios of approximately three, while the cells of lateresponding tissues have lower α/β-ratios. The alpha, beta, D50, m, and n values used for each
evaluation are shown in appendix B.
2.4 Statistical Analysis
The mean dose, V2.5, V5, V10, V20, and V30 of different scans were compared for
statistical analysis. In addition, the skin surface dose of the prone and supine techniques—from
the surface to a depth of 5 mm—for both grid sizes was evaluated for statistical analysis. The
dosimetry parameters of the heart, LV, LAD, left lung, and skin dose of each scan were compared
using a Wilcoxon signed-rank test for the related sample using the SPSS statistical software
(version 23.0 and 25.0), because the data had a non-normal distribution. The data were
considered to be statistically significant at P-value ≤ 0.05.
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Table 2.2 NTCP parameters for models used to evaluate OAR with specific end stage.
Structure

Organ
Model

Model

End
point/Stage

D50
(Gy)

Y

Alpha/Beta

Seriality

Parameter
N

Parameter
M

Reference

Heat

Heart

NTCP
Poisson-LQ

Mortality

52.4

1.3

3.0

1

NA

NA

Gagliardi et al., Br J Radiol.
1996; 69:839-84657

LV

Heart

NTCP
Poisson-LQ

Mortality

52.4

1.3

3.0

1

NA

NA

Gagliardi et al., Br J Radiol.
1996; 69:839-84657

LAD

Heart

NTCP
Poisson-LQ

Mortality

52.4

1.3

3.0

1

NA

NA

Gagliardi et al., Br J Radiol.
1996; 69:839-84657

Lung

Lung

NTCP
Lyman

Pneumonitis
(1), Grade >= 2

30.5

NA

3.0

NA

1

0.3

Kwa et al., Radiother Oncol
1998;48:61-6979

Lung

Lung

NTCP
Lyman

Pneumonitis
(2), Grade >= 2

30.8

NA

3.0

NA

0.99

0.37

Seppenwoolde et al., Int J
rad Onc bio, Phys,
2003;55:724-73578

Lung

Lung

NTCP
Lyman

Symptomatic
or
Radiographic
pneumonitis
(<= 6 months)

21.9

NA

3.0

NA

0.37

0.8

Moiseenko et al., Radiother
Oncol 2003;67:265-27480

Lung

Lung

NTCP
Lyman

Symptomatic
Pneumonitis
(<= 6 months)

21.0

NA

3.0

NA

1.02

0.26

Moiseenko et al., Radiother
Oncol 2003;67:265-27480

Lung

Lung

NTCP
Lyman

Symptomatic
or
Radiographic
Fibrosis (> 6
months)

28.8

NA

3.0

NA

0.34

0.5

Moiseenko et al., Radiother
Oncol 2003;67:265-27480

Lung

Lung

NTCP
Lyman

Symptomatic
Fibrosis (> 6
months)

25.0

NA

3.0

NA

0.15

0.85

Moiseenko et al., Radiother
Oncol 2003;67:265-27480
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Chapter 3: Objective of the Dissertation
The purpose of this research is to compare the dose to OARs and the skin dose for leftsided breast RT with comparable planning target volume coverage. This study primarily uses four
techniques to compare the dose to OAR: SFB, SDIBH, PFB, and PDIBH techniques. In addition,
it compares the skin dose of the SFB and PFB techniques, from the surface to a 5 mm depth. The
objective of this study is to determine the best treatment technique to spare the heart without
compromising the PTV coverage and underdosing skin. This study additionally provides
guidelines to implement DIBH in clinics that do not have the software, state-of-the art technology
(such as real-time position management system), surface mapping, and devices for involuntary
breath holds.
This dissertation comprises three studies: first, the three treatment positions SFB, SDIBH,
and PFB were compared for the same patient. In this study the dosimetric evaluation of OAR is
recorded and a statistical comparison was performed. In addition, an evaluation was performed
based on the small or large breast volume of the patient, i.e., left breast volume < 750 cm3 and
>= 750 cm3. Second, the four treatment positions SFB, SDIBH, PFB, and PDIBH were
dosimetrically compared and evaluated for statistical significance. In addition, a biological
evaluation of the OAR was performed for all the four techniques. These studies provide clinicians
with both DVH based dosimetric comparison and various biological model based biological
evaluations of OAR in all four techniques. The radiobiological evaluation models with cardiac
mortality as the endpoints were used to evaluate the NTCP for heart, LV, and LAD. For the lungs,
six possible endpoints available in the Eclipse TPS were used for radiobiological evaluation. Thus,
the second study additionally provides optimum guidelines based on the NTCP of OAR to find the
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most suitable techniques with respect to radiobiological evaluation of left-sided breast cancer
treatment. Third, the dose to the skin surface of the SFB and PFB techniques was compared. The
skin dose in breast cancer radiation treatment is an important factor in balancing the outcomes
and cosmesis. Skin toxicity is often considered a dose-limiting factor, and the skin dose can be
ignored in breast treatment and underdosing because it could cause recurrence. Thus,
understanding the skin dose for each treatment technique help radiation oncologists in choosing
the appropriate plan for treatment. In this study, therefore, the dose was evaluated from the
surface to a depth of 5 mm for both prone and supine techniques. Additionally, two different grid
calculation sizes of 1.0 mm and 2.5 mm were used to evaluate the influence of grid size on dose
calculation in the superficial region for prone and supine techniques.
Evaluating the current treatment techniques for breast cancer enables health care
providers to provide better disease control and care for these patients. To comprehensively
evaluate the performance of these techniques, understanding and evaluating them dosimetrically,
as well as radiologically, is important. Thus, the results of these three studies provide clinicians
with a complete overview, knowledge, and comparison of the various techniques to make an
informed decision on the best treatment technique for each patient undergoing RT for left-sided
breast cancer. In this study, only the 3D tangent techniques were evaluated, and IMRT or VMAT
treatment planning was not performed to evaluate the dose to OAR; these techniques must be
evaluated for OAR doses. Further, we did not perform a physical measurement of the skin dose
using trans-luminescent dosimeters (TLD) or diodes on the patient. This can be considered and
evaluated in the future.
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Chapter 4: Discussion 2
4.1 First Study
The results of our first study suggest that the mean heart dose can be reduced by almost
half using the SDIBH and PFB techniques compared with that using the SFB technique. When
the patient takes a deep breath, the heart moves posteriorly and inferiorly because of lung
expansion and diaphragmatic movements, consequently moving away from the chest wall. The
moving of heart during SDIBH helps reduce the volume of heart in the treatment field, thereby
reducing the dose to the heart and its components. The mean dose and all the dosimetric
parameters were the lowest in PFB for the LV. It is believed that the dose to the LAD plays a
crucial role in radiation-induced cardiac toxicity.51,52 The mean dose to the LAD in SDIBH and
PFB was found to be similar, and the highest mean dose was observed in SFB. In a similar study,

Table 4.1 Dosimetry parameters (median values and quartiles) in supine free-breathing (SFB),
supine deep inspiration breath-hold (SDIBH), prone free-breathing (PFB), and prone deep
inspiration breath-hold (PDIBH) techniques for heart, left ventricle (LV), left anterior descending
artery (LAD), and left lung. Please note that all dosimetric parameters are highest in SFB.
OAR

SFB

SDIBH

PFB

Heart

1.92 (1.42–2.76)

1.08 (0.84–1.36)

0.98 (0.83–1.15)

LV

3.19 (2.25–4.24)

1.50 (1.15–1.80)

1.34 (1.13–1.54)

LAD

21.73 (8.55–28.5)

6.30 (3.51–9.31)

6.57 (3.99–9.49)

Left lung

5.63 (4.23–6.86)

5.54 (4.29–6.42)

0.61 (0.47–0.80)

2
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Verhoeven et al.19 concluded that PFB results in higher doses to the heart and LAD than the SFB
and SDIBH techniques. However, the results of our study10 are different because both SDIBH and
PFB result in lower heart and LAD doses than that in SFB, irrespective of the breast volume.
We found equivocal results related to the reduction of radiation doses to the heart in PFB
in a literature study. However, all studies agree that the lung dose is drastically reduced in PFB
compared with the doses in SFB and SDIBH.6-8,16-19 Similarly, in our study, we found that the lung
doses are significantly lower in PFB than in SFB and SDIBH. The lung density of the irradiated
lung volume decreases in SDIBH as well.7,19,21 10,15,30 A study has indicated that an opposite effect
occurs in PFB, when the lungs are pushed downward by gravity, consequently increasing the lung
density.19 However, PFB exhibits clear advantages over SFB and SDIBH in lowering lung doses
and the values of most other dosimetric parameters compared with SFB in this study.
We could not find any other study in the literature that evaluates the heart, LV, LAD, and
lung for V2.5, V5, V10, V20, and V30, and statistically compares the dosimetric parameters of the
techniques and the dosimetric differences in OAR for SFB, SDIBH, and PFB with respect to the
breast volume. The mean doses evaluated for each OAR increased in SFB and SDIBH in
ascending order of small to large breast volumes of patients, as shown in Table 3. This can be
attributed to the fact that, with the increase in breast volume, the separation between the fields
increases, thus irradiating a larger volume to sufficiently cover the PTV. Further, a large breast
volume requires wider beams to be covered, thereby radiating a larger volume in SFB and SDIBH,
resulting in higher doses to the cardiac components and the lung.
An interesting observation is that differences between the doses and dosimetric
parameters evaluated for SFB and SDIBH, and for SFB and PFB, increased in the order of small
to large breast volumes of patients, as shown in Table 3. The dosimetric parameters are the
lowest for PFB for patients with breast PTV volume >= 750 cm3. Thus, the SDIBH and PFB
techniques are more beneficial than SFB for patients with large breasts.

29

4.2 Second Study
In this study, we intended to find if the DIBH in the prone position produces additional
benefits in sparing the heart and its components. The mean heart dose and mean LV dose in
PDIBH are statistically and significantly lower than those in SFB, SDIBH, and PFB. The PDIBH
exhibits a statistically significant reduction in mean LAD dose compared with SFB and PFB;
however, no significant difference was found with respect to SDIBH. The PFB produces
statistically and significantly lower mean heart and LAD doses compared with the SFB, which is
in contrast with a study that concluded that PFB gives a higher dose. It has been reported that an
increased risk of stenosis in the LAD exists for left-sided breast cancer patients.52

Table 3.2 Mean dosimetric parameters (median values and quartiles) of OAR in SFB, SDIBH, and
PFB based on breast PTV volume < 750 cm3 and >= 750 cm3. Please note that PFB has the
lowest mean values for heart, LV, LAD, and lung for breast PTV volume >= 750 cm3.
Breast PTV volume <
750 cm3

SFB

SDIBH

PFB

Mean heart dose (Gy)

1.65 (1.12–2.32)

0.87 (0.71–1.21)

0.90 (0.81–1.10)

Mean LV Dose (Gy)

2.93 (1.85–4.04)

1.30 (1.01–1.70)

1.32 (1.13–1.50)

Mean LAD dose (Gy)

19.86 (7.85–25.1)

5.97 (3.01–8.53)

6.5 (3.58–9.16)

Mean lung dose (Gy)
Breast PTV volume >=
750 cm3

5.48 (3.93–6.52)

5.06 (4.09–6.38)

0.61(0.48–0.97)

Mean heart dose (Gy)

2.59 (1.87–4.06)

1.36 (0.97–1.62)

1.07 (0.87–1.31)

Mean LV Dose (Gy)

3.61 (3.02–5.77)

1.72 (1.40–2.11)

1.2 (1.11–1.58)

Mean LAD dose (Gy)

24.74 (10.22–36.75)

7.05 (3.27–12.99)

6.7 (4.51–9.93)

Mean lung dose (Gy)

5.69 (4.77–7.08)

5.7 (5.23–7.06)

0.57 (0.36–0.68)

Higher LAD dose in PFB compared with the SDIBH could be attributed to the fact that the
LAD falls close to mediastinum/chest wall because of gravity, which causes it to be closer to the
treatment field; however, in PDIBH, it lowers because the deep inspiration pushes the proximity
of LAD away from the treatment field. The QUANTEC group81 recommends that, for breast cancer
patients, the irradiated heart volume should be minimized without compromising the target
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coverage. Our results in Table 5 conclusively indicate that the PDIBH further reduces the dose to
heart, LV, and LAD compared with SFB, SDIBH, and PFB.
The mean lung doses and other dosimetric parameters evaluated in PFB and PDIBH are
statistically lower than those in SFB and SDIBH. In the prone position, the minimal beam
propagates through the lung because of the pulling away from the breast from the chest wall and
lung. Thus, the prone set up has a clear advantage over the supine set up in lowering the lung
doses and the other dosimetric parameters calculated in this study, which are in agreement with
those of several previous studies.6-10,16-18 However, similar to a study by Thomas et al.,11 we found
that the PFB administers a slightly lower lung dose than PDIBH, if the density correction caused
by increased lung volume of PDIBH is not considered. This could be because the heart volume
may have been replaced by the lung tissue in the irradiated volume; however, the increase in lung
volume could compensate the increase in dose to a small volume.

Table 4.3 Dosimetry parameters (median values and quartiles) in supine free-breathing (SFB),
supine deep inspiration breath-hold (SDIBH), prone free-breathing (PFB), and prone deep
inspiration breath-hold (PDIBH) techniques for heart, left ventricle (LV), left anterior descending
artery (LAD), and left lung.
OAR

SFB

SDIBH

PFB

PDIBH

Heart

1.88 (1.09–2.22)

0.97 (0.68–1.23)

0.85 (0.68–1.04)

0.77 (0.55–0.92)

LV

3.48 (2.21–4.60)

1.36 (0.97–2.32)

1.18 (0.98–1.34)

1.03 (0.80–1.22)

LAD

22.38 (5.34–26.19)

3.88 (2.59–7.98)

4.96 (3.45–6.56)

3.49 (2.30–5.12)

Left Lung

6.09 (4.89–7.86)

5.41 (4.80–6.75)

0.69 (0.47–0.87)

0.88 (0.62–1.31)

Further, although NTCP analysis is not currently used directly in radiotherapy plan
evaluation, it is a very important tool for comparing the radiotherapy plans and methods. An NTCP
analysis can also help find different methods to reduce radiotherapy-induced complication rates
for patients undergoing RT treatment.56,57,81-85 Therefore, we performed a biological evaluation of
each technique for the NTCP of OARs. Studies that compare the NTCP for OAR in SFB with
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SDIBH exist in the literature.82-84 However, no study was found that compares the NTCP for heart,
LV, LAD, and lung for supine and prone techniques. Moreover, our study is the first that calculates
and compares the NTCP values of prone techniques with those of supine techniques in freebreathing and deep inspiration breath-hold. In addition, ours is the only study that calculates the
NTCP for six endpoints of lung complications using the NTCP LKB model for each of the four
techniques (Table 6).
Based on the biological evaluation of heart with cardiac morbidity, we found statistically
and significantly lower NTCP for SDIBH, PFB, and PDIBH techniques compared with the SFB,
which correlates with our result of lower dosimetry doses for heart for all techniques compared
with the SFB technique. A study has concluded that the SDIBH, PFB, and PDIBH techniques
significantly reduce the mean probability of both excessive cardiac mortality and lung complication
compared with the SFB technique. Our results are similar to those of a few studies that concluded
that the SDIBH significantly reduces the probability of heart and lung complication compared with
SFB.82-84 In our study, we did not find any statistically significant difference in NTCP between the
SDIBH, PFB, and PDIBH for heart, LAD, and LV. Both the prone techniques PFB and PDIBH
showed that the NTCP of lung complication is statistically significant compared with the SFB and
SDIBH, which correlates with the lower dosimetry dose in the lung between these techniques.
4.3 Third Study
Measuring the skin dose for tangential beams is difficult. Although skin dose has been
studied relatively deeper, it could still be ignored. Most TPS is known to provide inaccurate dose
estimates.71,86,87 Conventional model-based dose calculation algorithms have limitations at the
buildup region because of the lack of electron equilibrium and incomplete scatter conditions close
to the skin and air surface. This are caused by difficulties in modeling the contribution of dose
from electrons originating from the primary photons interacting with a part of the LINAC, flattening
filter, and collimators by the planning system. A study has concluded that the accuracy of AAA in
a solid water phantom for tangential treatment plans is comparable to that of the Monte Carlo
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method.88 However, another study has concluded that the AAA algorithm cannot predict the dose
reliably at depths less than 2 mm.89 Panettiere et al.90 measured the calculation accuracy of AAA
in the surface build region in tangential beam arrangements similar to that in breast treatment
planning. It concluded that, for a 6 MV beam, using the AAA does not introduce clinically
significant error in the buildup region for absorbed dose, particularly after the initial 2 mm of tissue.

Table 4.4 Calculated NTCP values (median values and quartiles) in supine free-breathing (SFB),
supine deep inspiration breath-hold (SDIBH), prone free-breathing (PFB), and prone deep
inspiration breath-hold (PDIBH) techniques with end-stage for heart, left ventricle (LV), left
anterior descending artery (LAD), and the lung.
End point/Stage

Mean NTCP
(%) SFB

Mean NTCP
(%) SDIBH

Mean NTCP
(%) PFB

Mean NTCP
(%) PDIBH

Heart (Cardiac Mortality)

0.27 (0.010.55)

0 (0-0.01)

0 (0-0)

0 (0-0)

LV (Cardiac Mortality)

0.62 (0.0231.98)

0 (0-0.038)

0 (0-0)

0 (0-0)

LAD (Cardiac Mortality)

4.23 (0-14.77)

0 (0-0.26)

0 (0-0.07)

0 (0-0)

Lung Pneumonitis (1), Grade >= 2

0.12 (0.10.188)

0.1 (0.0820.13)

0.05 (0.050.05)

0.05 (0.050.05)

Lung Pneumonitis (2), Grade >= 2

0.69 (0.610.88)

0.62 (0.540.72)

0.36 (0.360.37)

0.37 (0.360.39)

Lung Symptomatic or Radiographic
Pneumonitis (<= 6 months)

30.24 (28.1134.52)

28.56 (25.2030.97)

12.47 (11.9514.40)

14.04 (12.5116.79)

Lung Symptomatic Pneumonitis (< 6
months)

0.04 (0.030.073)

0.02 (0.020.04)

0.01 (0.010.01)

0.01 (0.010.01)

Lung Symptomatic or Radiographic
Fibrosis (> 6 months)

15.09 (13.4919.02)

13.85 (11.2315.89)

3.2 (2.92-4.22)

4.26 (3.265.83)

Lung Symptomatic Fibrosis (> 6 months)

51.81 (48.9554.64)

48.95 (45.9651.52)

23.47 (19.9928.48)

27.7 (22.5834.01)

Lung composite

41.32 (38.2147.41)

38.85 (33.9542.36)

15.57 (14.8218.30)

17.79 (15.7521.76)

Many studies have evaluated various methods to verify the skin dose, but skin dose is not
one of the parameters recorded—unlike OARs such as the heart and lungs.71,87,91 Skin dose, in
addition to being energy-dependent, can be grid size-dependent as well. A study has indicated
that a difference of up to 3% is observed in maximum and mean doses with a calculation grid.71
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A limitation of our study is that the dose on the patient’s surface during treatment was not
measured using diodes or TLDs.
In this study, the superficial doses of 50 patients were compared in the prone and supine
positions. The dose at depths of 3 mm, 4 mm, and 5 mm is statistically and significantly lower in
the prone position than in the supine position. The doses at 3 mm, 4 mm, and 5 mm are similar
for the prone position with calculation grid sizes of 1 mm and 2.5 mm; a similar observation is
made for supine position for both grid sizes (Table 7). Thus, minimal effects of grid size are
observed on dose at depths beyond 2 mm for prone and supine positions.

Table 4.5 Dose (median value and quartile range) in percentage from a depth of 0–5 mm for prone
and supine techniques with grid sizes of 1.5 mm and 2.5 mm, respectively.
Technique (Grid
size)

0 mm

1 mm

2 mm

3 mm

4 mm

5 mm

Prone (Grid size:
1.0 mm) dose in %

32.25
(29.48–
33.92)

66.87
(63.77–
68.11)

81.86
(80.26–
82.91)

87.80
(86.47–
88.90)

91.92 (90.90–
92.97)

95.30
(93.77–
96.00)

Supine (Grid size:
1.0 mm) dose in %

32.95
(30.55–
36.82)

65.05
(63.35–
67.99)

81.27
(79.50–
82.75)

89.10
(87.23–
90.36)

94.50 (92.57–
95.62)

98.20
(96.6–
99.51)

Prone (Grid size:
2.5 mm) dose in %

36.75
(33.3–
39.32)

60.38
(56.90–
64.08)

77.35
(74.55–
80.37)

87.1
(85.20–
88.31)

91.6 (90.27–
92.76)

95.10
(93.74–
96.00)

Supine (Grid size:
2.5 mm) dose in %

38.16
(32.82–
42.32)

62.15
(57.27–
67.50)

79.65
(76.77–
81.75)

88.59
(86.68–
90.14)

94.63 (92.85–
95.34)

97.8
(96.71–
99.44)

An optimum surface dose must realize the primary objective of treating breast cancer
without excessive skin toxicity, such as erythema, desquamation, edema, and fibrosis. The dose
beyond the depth of 2 mm is up to 3% lower in the prone technique compared with that in the
supine technique. As mentioned earlier, the beam incidence angle is close to perpendicular in the
prone technique, which may lead to lower superficial dose in the prone technique than supine
technique. The inadequate superficial dose could lead to recurrence. Further, as indicated by
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Katz et al.,69 if a lumpectomy bed is close to the skin surface, it is important to consider the dose
in case the clinician considers treating using the prone technique (Figure 4.1). A clinician should
consider lumpectomy or tumor bed contouring, particularly for patients treated in the prone
position, to evaluate the dose to the gross tumor volume. For such cases, boost treatment should
be considered to deliver sufficient dose to the tumor bed; this prevents underdosing of the
superficial tumor beds.
A statistically and significantly lower mean dose is delivered to all OAR in the prone
position compared with the supine position (Table 8). The heart, LV, LAD, and left lung doses are
significantly lower in the prone position. As mentioned earlier, the heart falls anteriorly in the prone
position because the breast falls and elongates because of gravity; thus, the beam angles can be
chosen to minimize the in-field heart, LV, and LAD doses. Similar to other studies, the largest
dose reduction is seen in the left lung in the prone position compared with the supine position.6,8,10
However, on the contrary to a study by Verhoeven et al.19 that concluded that LAD is
higher in the prone position, we found a statistically significant dose reduction in LAD for the prone
position compared with the supine position. Thus, we were able to reduce the dose to all the OAR
in the prone position. Therefore, this is the only study that compares the skin dose in the prone
and supine positions for the same patient, along with comparison of dose for OAR.

Table 4.6 Dose (median value and quartile range) in Gy for OAR in prone and supine positions.
Mean Dose for OAR

Prone Position

Supine Position

Heart Dose (Gy)

0.92 (0.72–1.11)

1.88 (1.42–2.58)

LV Dose (Gy)

1.31 (1.02–1.5)

3.24 (2.27–4.42)

LAD Dose (Gy)

5.81 (3.71–8.6)

21.76 (6.83–26.88)

Lung Dose (Gy)

0.65 (0.48–0.85)

5.74 (4.55–6.98)
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(a)

(b)

Figure 4.1 (a) Prone and (b) Supine treatment techniques with 100% isodose line. Yellow line
represents 100% isodose line, and orange, red, and pink contours represent breast PTV,
lumpectomy, and heart, respectively.
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Chapter 5: Conclusion 3
We conclude that the radiation dose to the heart, LV, LAD, and left lung can be significantly
reduced by selecting the appropriate technique. Based on the data of the first study, we can
conclude that PFB is preferred dosimetrically over the SFB and SDIBH techniques. Although the
first study analyzed the data based on the breast volume, we conclude that—irrespective of the
breast volume—PFB is more beneficial than the SFB technique for OAR sparing. The SDIBH and
PFB technique deliver lower doses to cardiac components than the SFB technique. The PFB
technique delivers significantly lower lung doses than the SFB and SDIBH techniques. Thus, the
PFB technique could be recommended for patients with pulmonary diseases.
In our second study, we included the PDIBH technique for evaluation, along with the SFB,
SDIBH, and PFB techniques. Deep inspiration breath-hold in prone position has additional
benefits in lowering heart, LV, and LAD doses compared with the SFB, SDIBH, and PFB
techniques. The dosimetric findings are augmented with the NTCP for cardiac mortality, indicating
that a substantial reduction can be achieved using SDIBH, PFB, and PDIBH compared with the
SFB. The left Lung doses and composite NTCP for lung complications are statistically lower in
the prone techniques than in the supine techniques. Thus, the PDIBH is more significantly
beneficial in heart, LV, LAD, and lung sparing than the SDIBH. We conclude that a significant
dose reduction can be achieved using the prone technique. Each clinic should not only evaluate
the advantages and disadvantages of each technique but also consider the patient comfort level
and breathing patterns when selecting the breast technique. Better integration of biological

3
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models in TPS with validated input parameters (α and β) for the OAR may facilitate adoption for
clinical practice.
Our third study concluded that based on the same patient population in the prone and
supine patients treated with a 6 MV beam, the dose to OAR is lower in the prone position,
particularly for LAD and left lung. Further, the skin dose is lower in the prone position than the
supine position, which could probably result in skin recurrence. The dose from the skin surface
increases rapidly in both techniques to more than 95% at a depth of 5 mm. This confirms our
hypothesis that the prone technique delivers a lower superficial dose than the supine technique,
irrespective of the calculation grid size. Because the beam angle in the prone technique is almost
perpendicular to the surface, this observation is accurate with physical parameters. The clinician
should additionally consider routinely contouring the tumor bed, particularly for patients to be
treated with prone positions, to evaluate the dose to the gross tumor volume; this helps avoid
underdosing of superficial tumor beds. Thus, the prone position reduces the dose to the OAR;
however, the dose to the skin may also be assessed in the prone technique, and if desired, the
skin dose could be carefully augmented via a bolus or beam spoiler.
Based on these results and findings, we conclude that the PDIBH technique spares the
heart and its components the most, whereas the PFB technique spares the lung the most in
addition to adequately sparing the heart components. Furthermore, prone free-breathing
techniques are the most suitable for patients with pulmonary issues. No statistically significant
difference was found between the NTCP of SDIBH, PFB, and PDIBH techniques for heart, LV,
and LAD. The PFB technique has a statistically and significantly lower lung NTCP than the SDIBH
and PDIBH techniques. Thus, radio biologically, we conclude that prone free-breathing is the most
suitable technique for sparing OAR.
However, recurrence could occur because of underdosing of skin. In cases where skin
dose is a concern, such as when a tumor is close to the skin surface, physicians can use the
SDIBH technique to spare the heart and its components. Furthermore, the prone technique can
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be utilized with bolus or beam spoilers to increase the skin dose, if the lung function of the patient
is compromised.
5.1 Future Work
Future work should include the IMRT and VMAT techniques in conjunction with the SDIBH
and prone techniques for sparing of OAR, along with NTCP evaluation. In addition, the dose to
the skin must be measured at various depths on the phantom to validate the dose calculated by
the treatment planning system at a superficial depth. For future studies, the radiobiological model
must be further evaluated, and the results should be clinically validated for clinical application on
a regular basis. Further, radiobiological models with different α and β ratios need to be examined.
Furthermore, these results must be confirmed by a long-term study on the effects on patients,
after a few decades from the administration of the RT treatment.
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Abbreviations
3D: Three-dimensional
AAA: Anisotropic Analytic Algorithm
ABC: Active Breathing Control
BC: Breast Cancer
BCS: Breast-Conserving Surgery
BEV: Beams Eye View
CT: Computed Tomography
CTV: Clinical Target Volume
DV: Dose Volume
DVH: Dose Volume Histogram
GTV: Gross Tumor Volume
HU: Hounsfield Unit
IMRT: Intensity Modulated Radiation Therapy
LAD: Left Anterior Descending Artery
LINAC: Linear Accelerator
LQ: Linear Quadratic
LV: Left Ventricle
MLC: Multi Leaf Collimator
MV: Mega Voltage
NTCP: Normal Tissue Complication Probability
OAR: Organs AT Risk
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PDIBH: Prone Deep Inspiration Breath Hold
PFB: Prone Free Breathing
PTV: Planning Target Volume
RPM: Real Time Position Management
RT: Radiation Therapy
SDIBH: Supine Deep Inspiration Breath Hold
SFB: Supine Free Breathing
TCP: Tumor Control Probability
TPS: Treatment Planning System
TX: Treatment
V10: Volume of Organ Getting 10 Gy of Dose
V2.5: Volume of Organ Getting 2.5 Gy of Dose
V20: Volume of Organ Getting 20 Gy of Dose
V30: Volume of Organ Getting 30 Gy of Dose
V5: Volume of Organ Getting 5 Gy of Dose
VMAT: Volumetric Modulated Arc Therapy
CRT: Conformal Radiation Therapy
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Appendix A: Lasers Based DIBH Procedure
A.1 Procedure 1: Computed Tomography (CT) Scan with Lasers Based DIBH
CT Scan in free-breathing and deep inspiration breath-hold using Lasers & cameras in the
CT simulation room.
A.1.1 Prepare Patient
1. Bring the patient into room, explain the CT sim procedure.
2. Explain to the patient the DIBH procedure.
a. Two coaching sessions will be done to learn the extent of patients’ ability to hold the
breath for a sufficient period (usually 20 seconds or more) at a maximum inhalation
point. (Deep inspiration breath should be to a higher-than-normal level. The patient
should not be able to reach this higher level when breathing normally.)
b. Specific instructions will be given verbally to achieve deep inspiration breath-hold.
c. The first session occurs in the CT room where the patient is coached to follow the
verbal commands and hold the breath for 20+ seconds.
d. The second session occurs using the free-breathing and breath-hold mark on the
patient, where the consistent DIBH position will be determined.
3. Place patient on CT Table; for the supine position with both arms above head in Vac Lok,
head turned to the unaffected side, knee sponge under knees; for prone position use
prone board
4. Call the doctor into the wire scar and the breast.
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5. Let patient breathe freely, once a patient is breathing normally, then place a mark on the
patient with a sharpie where the isocenter of treatment lies during the free-breathing (2
lateral side marks and 1 mark anteriorly on the chest) with respect to fixed lasers
6. Instruct the patient to take in a deep breath and hold it, then place a mark on the patient
with a sharpie where the iso lies during the breath-hold (2 lateral side marks and 1 mark
anteriorly on the chest) with respect to lasers. Let the patient breath.
7. Please note down the distance between marks in free-breathing and breath-hold in
anterior/posterior and superior/inferior directions.
8. Repeat Breath-hold after 2 minutes to ensure consistency of the breath-hold.
9. Ensure 2 dots of the patient are visible on an outside monitor attached to verify breathhold during the scan. Adjust the camera if needed.
10. Ensure that lasers are on free-breathing marks with respect to lasers placed before freebreathing scan place marks and BB’s on the patient.
11. Scan the patient with a free-breathing technique.
12. Begin in-room DIBH coaching first session.
13. Issue verbal commands
a. Relax and breathe normally
b. Take in a deep breath and (on my command), hold your breath
c. Breathe
14. Practice this with the patient, 2-3 times, aiming for a breath-hold of 20 seconds
a. Make sure patient marks are lined up and have the patient take a deep breath in and
hold checking the breath-hold marks for consistency. Have the patient breath.
15. Ask the patient to take a deep breath and hold.
16. Scan the patient in breath-hold and ask the patient to breath as soon as the scan is over.
17. If the patient releases breath-hold or breath-hold drifts out of marked position w.r.t lasers,
stop CT scan and repeat scan.
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18. Have the patient relax and breathe normally.
19. If the patient is unable to hold the breath for 20 seconds, the patient may not be a
candidate for DIBH. Consult with Physicians and Physics on how to proceed.
20. Take photos of set up and complete normal simulation tasks.
21. Explain to the patient that between now and when they return, they need to practice taking
a deep breath in and holding it for 20-30 seconds several times a day. Let the patient
dress. Explain that it takes approximately 1 week to complete the plan. And that we will
call to schedule their first appointment as soon as the plan is complete and insurance
authorizations are obtained.
A.2 Procedure 2: Treatment Procedure with Lasers Based DIBH
DIBH Treatment delivery using Lasers and High definition cameras installed in the treatment
room with monitors located at the treatment console.
A.2.1 Prior to Bringing the Patient into the Treatment Room
1. Mode up the patient on Varian 4DITC.
2. Have the DIBH number paper printed with information on the distance between Freebreathing to DIBH marks on the patient along with the isocenter numbers.
A.2.2 Prepare Patient
1. Bring the patient into the room and give an overview as to what will occur during the new
start procedure.
2. Review the DIBH procedure.
3. Position patient on the treatment table according to the simulation setup worksheet.
4. Align the patient to simulation marks.
5. Perform dosimetry shifts from the treatment plan. (Initial new Start)
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6. Ensure that the High definition camera is on and zoom it to see the lasers on the freebreathing and the DIBH marks placed on the patient from outside. Adjust camera position
if necessary.
A.2.3 Patient Coaching from Treatment Console
1. Prepare the HD camera and adjust so you can see the marks on the patient’s skin clearly
w.r.t lasers.
2. Coach patient on deep-inspiration-breath-hold via in-room speaker.
a. Allow the patient to relax
b. Give patient-specific instructions designed to achieve deep inspiration breath-hold
i. Relax and breathe normally.
ii. Take in a deep breath and (on my command), hold your breath.
iii. Verify using outside monitor attached to High definition cameras
iv. Confirm patient here at the breath-hold position for the required amount of time ~
20 seconds.
v. Instruct the patient to breathe normally.
c. Repeat Step 2 a few times to determine patient can consistently
achieve the DIBH position.
A.2.4 Perform Pretreatment Verification/Filming (KV)
1. Mode up KV field, move imager arms into position.
2. Give patient-specific instructions designed to achieve deep inspiration breath-hold.
a. Relax, breath normally.
b. Take in a deep breath and (on my command), hold your breath
c. Ensure that the patient achieves breath-hold position w.r.t marks on patients and
lasers.
3. Press and hold footswitch/hand switch to acquire KV Image.
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a. (Press and hold the footswitch/hand switch several seconds before the beginning
threshold is reached. This ensures that the tube is prepped in time for the X-Ray
signal.)
4. Ask the patient to relax and breathe normally.
5. Repeat steps 2 through 5 for each image taken.
Note: When imaging is occurring, the image area displays the fluoroscopic image rather
than the camera view.
6. Apply couch shifts at the Clinac Console.
7. Repeat KV images following steps 2 through 5 (based on the size of table shifts and
Department protocol) and Step #8 if shifts are again applied.
8. Retract KV imager arms.
A.2.5 Perform Pretreatment Verification/Filming (MV)
1. Mode up MV image fields, move imager into position.
2. Turn on the Clinac key to Beam -On and the Clinac is in a green Ready State.
3. Give patient-specific instructions designed to achieve deep inspiration breath-hold.
a. Relax, breath normally.
b. Take in a deep breath and (on my command), hold your breath.
c.

Ensure that the patient achieves breath-hold position w.r.t marks on patients and
lasers.

4. While the patient is in breath-hold, Beam On.
5. Mode up 2nd portion of double image and Beam On while the patient remains in breathhold state.
6. After a double exposure port completed, ask the patient to relax and breathe normally.
7. Repeat steps 1 thru 6 for each image taken.
(Note: When imaging is occurring, the image area displays the fluoroscopic image rather
than the camera view.)
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8. Apply couch shifts at the Clinac Console.
9. Repeat MV images following steps 1 through 6 (based on the size of table shifts and
Department protocol) and Step #9 if shifts are again applied.
10. When imaging is complete click Stop. Do not enter Exam or Series #. Cancel.
11. Retract imager.
A.2.6 Begin Treatment
1. Mode up treatment field.
2. Give patient-specific instructions designed to achieve deep inspiration breath-hold.
a. Relax, breath normally.
b. Take in a deep breath and (on my command), hold your breath.
3. Ensure that the patient achieves breath-hold position w.r.t marks on patients and lasers.
4. While the patient is in breath-hold, Beam-on the treatment field.
8. Monitor the breath-hold using an HD camera
9. Mode up the next treatment field and follow steps 6 thru 8.
10. When all fields have been completed, click Stop.
11. Do not enter Exam or Series #, select Cancel.
12. Click Close Patient in the session panel.
13. Select Close in the Patient List dialog box and Exit program.
14. Turn the key in the gating switch box to the Disabled position to return the Clinac to nongated operation.
15. Shutdown gating computer.
16. Turn off in the room camera.
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Appendix B: Biological Evaluation Models and Parameters

Figure B.1 Organ: heart; end point/stage: cardiac mortality; model: NTCP poisson-LQ.
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Figure B.2 Organ: lung; end point/stage: pneumonitis (1) grade >=2; model: NTCP lyman.

Figure B.3 Organ: lung; end point/stage: pneumonitis (2) grade >=2; model: NTCP lyman.

56

Figure B.4 Organ: Lung; End point/stage: Symptomatic or Radiographic pneumonitis (<=6
months); Model: NTCP Lyman.

Figure B.5 Organ: lung; end point/stage: symptomatic or radiographic pneumonitis
(<=6 months); model: NTCP lyman.
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Figure B.6 Organ: lung; end point/stage: symptomatic or radiographic fibrosis; model: NTCP
lyman

Figure B.7 Organ: lung; end point/stage: symptomatic fibrosis (>6 months); model: NTCP lyman
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Appendix C: Published Study 1—Evaluation of Sparing Organs at Risk in Left-Sided
Breast Irradiation in the Supine and Prone Positions with Deep Inspiration Breath Hold
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Appendix D: Published Study 2—Biological Indices Evaluation of Various Treatment
Techniques for Left-Sided Breast Treatment
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Appendix E: Submitted Study 3—Skin Dose in Radiation Treatment of Left Breast:
Analysis in the Context of Prone Versus Supine Treatment Techniques
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Appendix F: Permission to Publish Study 1
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Appendix G: Permission to Publish Study 2
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